Cumulus Neuroscience and Interaxon Inc. (Muse) have announced a collaboration to integrate Muse's at-home sleep EEG technology into the NeuLogiq multi-modal platform for central nervous system (CNS) clinical trials. The partnership adds objective, brain-based sleep measurement to the platform, addressing a critical need in neuropsychiatric and neurodegenerative research.
Sleep as a Biomarker in CNS Research
Sleep disturbances are common in neuropsychiatric and neurodegenerative disorders, serving as both a symptom and a driver of disease progression. Disrupted deep sleep has been linked to impaired amyloid clearance and cognitive decline, making sleep an increasingly important therapeutic target and biomarker. However, objective sleep measurement at scale has been challenging: in-lab polysomnography (PSG) is burdensome and costly, while most wearables infer sleep indirectly from movement and heart rate.
NeuLogiq Sleep Domain Powered by Muse
Through this collaboration, the NeuLogiq Platform sleep domain is powered by Muse—a soft, at-home EEG wearable that directly reads brain activity, resolving slow waves, spindles, and K-complexes that define each sleep stage. Muse scores full sleep architecture at 88–96% agreement with gold-standard PSG, according to a 2025 study in SLEEP Advances by Lanthier et al. This enables trial-grade sleep staging captured in the participant's own home, with low patient burden and repeatability suitable for longitudinal CNS studies, alongside NeuLogiq core measures of cognition, wake EEG, mood, and speech.
Industry Leaders Comment
“Objective, reliable longitudinal data are needed to advance CNS clinical development programs, which have relied on subjective measures for too long,” said Tina Sampath, Cumulus CEO. “Integrating Muse into the NeuLogiq Platform allows us to bring multi-modal measures—wake and sleep EEG, cognition, mood and speech—out of the clinic and into study participants’ homes at scale, accelerating data collection and enabling earlier decision-making in clinical trials.”
Jean-Michel Fournier, CEO of Muse by Interaxon, added: “The Muse S Athena was built to read the brain directly, at home, at scale, with best-in-class user comfort and ease-of-use at the fore. It has been proven with more than 16.8 million nights across 500,000+ real-world users. Bringing that to NeuLogiq means researchers can finally treat sleep as the objective, repeatable measure it should be in CNS trials, without sending participants to a lab.”
Presentation at AAIC 2026
The companies will present these integrated NeuLogiq Platform capabilities at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12-15, at the Cumulus Booth #712.
About the Companies
Muse by Interaxon is headquartered in Toronto, Canada, and pioneers brain health through its EEG platform built on advanced AI. Its tools are underpinned by over 200 third-party studies from institutions including the Mayo Clinic, MIT, and Harvard. The company has decoded over one billion minutes of brain data, one of the largest EEG collections in the world. Cumulus Neuroscience is a global digital health company focused on advancing neuroscience clinical trials and patient care through improved data.
